Dr. Reddy's To Acquire Haleon's Global Portfolio Of Consumer Healthcare Brands In The Nicotine Replacement Therapy, Building On Its Global Consumer Healthcare Business; Financial Terms Not Disclosed

Author: Benzinga Newsdesk | June 26, 2024 11:29am

Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States

• Acquisition seen as ideal anchor to continue to build the company's global consumer healthcare OTC business
• In recent years, Dr. Reddy's has increased its presence in consumer healthcare (nutrition and OTC wellness) in markets around the world, including a recent joint venture with Nestlé India

Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), a global pharmaceutical company, today announced that its subsidiary Dr. Reddy's Laboratories SA has signed a definitive agreement with Haleon plc (NYSE:HLN, ", Haleon", ))))), a leading consumer healthcare company, for purchase of shares of Northstar Switzerland SARL, a Haleon group company, to acquire Haleon's global portfolio of consumer healthcare brands in the Nicotine Replacement Therapy ("NRT") category outside of the United States. The portfolio to be acquired consists of Nicotinell, a global leader in the NRT category with an extensive footprint in over 30 countries spanning Europe, Asia including Japan, and Latin America, and local market-leading brand names of the product – Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand and Canada. The proposed acquisition will be inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global markets outside of the United States.

Posted In: HLN RDY